Jason Zemansky
Stock Analyst at B of A Securities
(4.89)
# 39
Out of 5,165 analysts
53
Total ratings
78.38%
Success rate
47.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Initiates: Buy | $244 | $207.80 | +17.42% | 1 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $11.95 | +184.52% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.98 | +203.03% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $11.03 | +72.26% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $22.45 | +15.81% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $4.87 | +64.27% | 5 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.81 | +763.13% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $144.60 | +29.32% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $60.83 | -7.94% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $28.03 | +10.60% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $29 | $8.73 | +232.19% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $24.04 | +28.95% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $2.69 | -7.06% | 5 | Jun 20, 2024 |
Ligand Pharmaceuticals
Mar 11, 2026
Initiates: Buy
Price Target: $244
Current: $207.80
Upside: +17.42%
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $11.95
Upside: +184.52%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.98
Upside: +203.03%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $11.03
Upside: +72.26%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $22.45
Upside: +15.81%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.87
Upside: +64.27%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.81
Upside: +763.13%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $144.60
Upside: +29.32%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $60.83
Upside: -7.94%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $28.03
Upside: +10.60%
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.73
Upside: +232.19%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $24.04
Upside: +28.95%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.69
Upside: -7.06%